On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs.
The bond between patients and healthcare providers has always been based on trust and transparency
The FDA’s approval of Zarxio, the first biosimilar product authorized for use in the United States, led to a flurry of predictions Friday about billions of dollars in savings and expanded access to treatment for patients. But what exactly are biosimilars, and why are they being hailed in this way?
Very recently during the 64th Legislature in the State of Washington, House Bill 1675 was introduced relating to the prescription of biological products and interchangeable biological products.
The U.S. Food & Drug Administration approved the first generic version of a biotech drug for domestic sale Friday, hours after Colorado state legislators wrestled with how to let pharmacists handle cheaper biotech drug knockoffs.
Patient advocates Kat Macfarlane and Candice Dusset were integral in the passing of Louisiana House Bill 319, which was signed into law on July 1st!
Dear Mr. Ginsberg,
Thank you for your June 12, 2015, letter to Acting Commissioner Ostroff on behalf of the Global Healthy Living Foundation regarding the labeling of biosimilars. Your letter was forwarded to the Center for Drug Evaluation and Research for response.
A recent decision by Facebook to limit the content we see in our newsfeeds could have far-reaching
and potentially deleterious unintended consequences for the global nonprofit and advocacy
The Global Healthy Living Foundation (GHLF) is a 501 (c)(3) patient group that works to improve the
quality of life for people with chronic disease, often focusing on those least able to advocate for
themselves. As a patient advocacy organization…
My name is Kathleen Hoffmann. I’m a patient advocate and member of the Global Healthy Living Foundation’s 50-State Network. I have been a resident of New Jersey for the last 33 years. I am currently in the process of…